Literature DB >> 27903714

Is ruxolitinib a potentially useful drug in hematological malignancies with RAS pathway hyperactivation?

Klaus Geissler1, Eva Jäger2, Agnes Barna3, Thamer Sliwa4, Paul Knöbl5, Ilse Schwarzinger2, Heinz Gisslinger5, Peter Valent5.   

Abstract

Entities:  

Keywords:  CMML; JMML; RAS; ruxolitinib

Mesh：

Substances：

Year:  2016        PMID： 27903714      PMCID： PMC5479601          DOI： 10.3324/haematol.2016.156448

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  10 in total

1.  Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency.

Authors:  Zohar Sachs; Raha A Been; Krista J DeCoursin; Hanh T Nguyen; Nurul A Mohd Hassan; Klara E Noble-Orcutt; Craig E Eckfeldt; Emily J Pomeroy; Ernesto Diaz-Flores; Jennifer L Geurts; Miechaleen D Diers; Diane E Hasz; Kelly J Morgan; Margaret L MacMillan; Kevin M Shannon; David A Largaespada; Stephen M Wiesner
Journal:  Haematologica       Date:  2016-07-14       Impact factor: 9.941

2.  In vitro and in vivo effects of JAK2 inhibition in chronic myelomonocytic leukemia.

Authors:  Klaus Geissler; Eva Jäger; Agnes Barna; Thamer Sliwa; Paul Knöbl; Ilse Schwarzinger; Heinz Gisslinger; Peter Valent
Journal:  Eur J Haematol       Date:  2016-06-15       Impact factor: 2.997

3.  A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML).

Authors:  Eric Padron; Amy Dezern; Marcio Andrade-Campos; Kris Vaddi; Peggy Scherle; Qing Zhang; Yan Ma; Maria E Balasis; Sara Tinsley; Hanadi Ramadan; Cassandra Zimmerman; David P Steensma; Gail J Roboz; Jeffrey E Lancet; Alan F List; Mikkael A Sekeres; Rami S Komrokji
Journal:  Clin Cancer Res       Date:  2016-02-08       Impact factor: 12.531

Review 4.  Chronic myelomonocytic leukemia: myeloproliferative variant.

Authors:  Francesco Onida; Miloslav Beran
Journal:  Curr Hematol Rep       Date:  2004-05

5.  Colony growth characteristics in chronic myelomonocytic leukemia.

Authors:  K Geissler; W Hinterberger; P Bettelheim; O Haas; K Lechner
Journal:  Leuk Res       Date:  1988       Impact factor: 3.156

6.  High spontaneous colony growth in chronic myelomonocytic leukemia correlates with increased disease activity and is a novel prognostic factor for predicting short survival.

Authors:  V Sagaster; L Ohler; A Berer; E Kabrna; P Ofner; K Lechner; K Geissler
Journal:  Ann Hematol       Date:  2003-09-13       Impact factor: 3.673

Review 7.  Mechanism of activation of the GM-CSF, IL-3, and IL-5 family of receptors.

Authors:  M A Guthridge; F C Stomski; D Thomas; J M Woodcock; C J Bagley; M C Berndt; A F Lopez
Journal:  Stem Cells       Date:  1998       Impact factor: 6.277

8.  Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells.

Authors:  G Bollag; D W Clapp; S Shih; F Adler; Y Y Zhang; P Thompson; B J Lange; M H Freedman; F McCormick; T Jacks; K Shannon
Journal:  Nat Genet       Date:  1996-02       Impact factor: 38.330

9.  Interleukin 10 inhibits growth and granulocyte/macrophage colony-stimulating factor production in chronic myelomonocytic leukemia cells.

Authors:  K Geissler; L Ohler; M Födinger; I Virgolini; M Leimer; E Kabrna; M Kollars; S Skoupy; B Bohle; M Rogy; K Lechner
Journal:  J Exp Med       Date:  1996-10-01       Impact factor: 14.307

10.  Chronic myelomonocytic leukemia patients with RAS pathway mutations show high in vitro myeloid colony formation in the absence of exogenous growth factors.

Authors:  K Geissler; E Jäger; A Barna; T Alendar; E Ljubuncic; T Sliwa; P Valent
Journal:  Leukemia       Date:  2016-08-18       Impact factor: 11.528
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.